LD50 = 280 mg/kg (mouse, oral)
Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholinesterases.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium. |
| Hydrocodone | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium. |
| Magnesium sulfate | The therapeutic efficacy of Hexafluronium can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Hexafluronium may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium. |
| Mirtazapine | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium. |
| Orphenadrine | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium. |
| Pramipexole | Hexafluronium may increase the sedative activities of Pramipexole. |
| Ropinirole | Hexafluronium may increase the sedative activities of Ropinirole. |
| Rotigotine | Hexafluronium may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Hexafluronium. |
| Sodium oxybate | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium. |
| Thalidomide | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Hexafluronium. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Hexafluronium. |
| Dipyridamole | The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Dipyridamole. |
| Ephedrine | Hexafluronium may increase the neuromuscular blocking activities of Ephedrine. |
| Clevidipine | Hexafluronium may increase the neuromuscular blocking activities of Clevidipine. |
| Sar9, Met (O2)11-Substance P | Hexafluronium may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P. |
| Mirabegron | Hexafluronium may increase the neuromuscular blocking activities of Mirabegron. |
| Moxisylyte | Hexafluronium may increase the neuromuscular blocking activities of Moxisylyte. |
| Propacetamol | Hexafluronium may increase the neuromuscular blocking activities of Propacetamol. |
| Procaine | Hexafluronium may increase the neuromuscular blocking activities of Procaine. |
| Cocaine | Hexafluronium may increase the neuromuscular blocking activities of Cocaine. |
| Trimethaphan | Hexafluronium may increase the neuromuscular blocking activities of Trimethaphan. |
| Doxacurium | Hexafluronium may increase the neuromuscular blocking activities of Doxacurium. |
| Chloroprocaine | Hexafluronium may increase the neuromuscular blocking activities of Chloroprocaine. |
| Tubocurarine | Hexafluronium may increase the neuromuscular blocking activities of Tubocurarine. |
| Aclidinium | Hexafluronium may increase the neuromuscular blocking activities of Aclidinium. |
| Bambuterol | Hexafluronium may increase the neuromuscular blocking activities of Bambuterol. |
| Butyrylthiocholine | Hexafluronium may increase the neuromuscular blocking activities of Butyrylthiocholine. |
| Oxybuprocaine | Hexafluronium may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Benzonatate | Hexafluronium may increase the neuromuscular blocking activities of Benzonatate. |
| Succinylcholine | The metabolism of Succinylcholine can be decreased when combined with Hexafluronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Botulinum toxin type B. |
| Ethanol | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Trazodone. |
| Sertraline | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Alaproclate. |
| Paroxetine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Paroxetine. |
| Escitalopram | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Escitalopram. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Levacetylmethadol. |
| Morphine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Hydromorphone. |
| Meperidine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Hexafluronium is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Hexafluronium is combined with Opium. |